

World Journal of *Gastroenterology*

World J Gastroenterol 2021 September 28; 27(36): 5989-6160



FRONTIER

- 5989** Fluorescent cholangiography: An up-to-date overview twelve years after the first clinical application
Pesce A, Piccolo G, Lecchi F, Fabbri N, Diana M, Feo CV

REVIEW

- 6004** Histone methylation in pancreatic cancer and its clinical implications
Liu XY, Guo CH, Xi ZY, Xu XQ, Zhao QY, Li LS, Wang Y
- 6025** Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan Africa: Implications for elimination of viral hepatitis by 2030?
Amponsah-Dacosta E

MINIREVIEWS

- 6039** Liver disease in the era of COVID-19: Is the worst yet to come?
Mikolasevic I, Bozic D, Pavić T, Ruzic A, Hauser G, Radic M, Radic-Kristo D, Razov-Radas M, Puljiz Z, Milic S
- 6053** Treatment of hepatitis B virus infection in children and adolescents
Stinco M, Rubino C, Trapani S, Indolfi G

ORIGINAL ARTICLE

Basic Study

- 6064** CircRNA_0084927 promotes colorectal cancer progression by regulating miRNA-20b-3p/glutathione S-transferase mu 5 axis
Liu F, Xiao XL, Liu YJ, Xu RH, Zhou WJ, Xu HC, Zhao AG, Xu YX, Dang YQ, Ji G
- 6079** Exosomal microRNA-588 from M2 polarized macrophages contributes to cisplatin resistance of gastric cancer cells
Cui HY, Rong JS, Chen J, Guo J, Zhu JQ, Ruan M, Zuo RR, Zhang SS, Qi JM, Zhang BH

Case Control Study

- 6093** Evaluation of biomarkers, genetic mutations, and epigenetic modifications in early diagnosis of pancreatic cancer
Rah B, Bandy MA, Bhat GR, Shah OJ, Jeelani H, Kawoosa F, Yousuf T, Afroze D

Retrospective Study

- 6110** Impact of radiogenomics in esophageal cancer on clinical outcomes: A pilot study
Brancato V, Garbino N, Mannelli L, Aiello M, Salvatore M, Franzese M, Cavaliere C

- 6128** Clinicopathological characteristics and longterm survival of patients with synchronous multiple primary gastrointestinal stromal tumors: A propensity score matching analysis

Wu H, Li C, Li H, Shang L, Jing HY, Liu J, Fang Z, Du FY, Liu Y, Fu MD, Jiang KW, Li LP

Observational Study

- 6142** Urotensin II levels in patients with inflammatory bowel disease

Alicic D, Martinovic D, Rusic D, Zivkovic PM, Tadin Hadjina I, Vilovic M, Kumric M, Tokic D, Supe-Domic D, Lupi-Ferandin S, Bozic J

CASE REPORT

- 6154** Inverted Meckel's diverticulum diagnosed using capsule endoscopy: A case report

El Hajra Martínez I, Calvo M, Martínez-Porras JL, Gomez-Pimpollo Garcia L, Rodriguez JL, Leon C, Calleja Panero JL

ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, Mark D Gorrell, BSc, PhD, Professor of Liver Science, Head, Liver Enzymes in Metabolism and Inflammation Program, Centenary Institute, Faculty of Medicine and Health, The University of Sydney, New South Wales 2006, Australia. m.gorrell@centenary.org.au

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Report® cites the 2020 impact factor (IF) for WJG as 5.742; Journal Citation Indicator: 0.79; IF without journal self cites: 5.590; 5-year IF: 5.044; Ranking: 28 among 92 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG's CiteScore for 2020 is 6.9 and Scopus CiteScore rank 2020: Gastroenterology is 19/136.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Jia-Hui Li; Production Department Director: Yu-Jie Ma; Editorial Office Director: Ze-Mao Gong.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski, Subrata Ghosh

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

September 28, 2021

COPYRIGHT

© 2021 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Fluorescent cholangiography: An up-to-date overview twelve years after the first clinical application

Antonio Pesce, Gaetano Piccolo, Francesca Lecchi, Nicolò Fabbri, Michele Diana, Carlo Vittorio Feo

ORCID number: Antonio Pesce 0000-0002-7560-551X; Gaetano Piccolo 0000-0002-4942-7705; Francesca Lecchi 0000-0002-7568-4967; Nicolò Fabbri 0000-0001-7039-3717; Michele Diana 0000-0002-1390-8486; Carlo Vittorio Feo 0000-0003-0699-5689.

Author contributions: Pesce A and Piccolo G designed the research; Pesce A, Piccolo G, Fabbri N, and Lecchi F researched and wrote the manuscript; Diana M and Feo CV supervised the paper; all authors have read and approved the final manuscript.

Conflict-of-interest statement: The corresponding author declares that the manuscript has been submitted on behalf of all authors. All authors declare that they have no competing interests.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/License>

Antonio Pesce, Nicolò Fabbri, Carlo Vittorio Feo, Department of Surgery, Section of General Surgery, Ospedale del Delta, Azienda USL of Ferrara, University of Ferrara, Ferrara 44023, Italy

Gaetano Piccolo, Francesca Lecchi, Department of Health Sciences, University of Milan, Unit of Hepato-Bilio-Pancreatic and Digestive Surgery, San Paolo Hospital, Milano 20142, Italy

Michele Diana, Department of General, Digestive and Endocrine Surgery, University Hospital of Strasbourg, IRCAD, Research Institute Against Digestive Cancer, ICUBE lab, PHOTONICS for Health, University of Strasbourg, Strasbourg Cedex F-67091, France

Corresponding author: Antonio Pesce, MD, PhD, Research Fellow, Surgeon, Department of Surgery, Section of General Surgery, Ospedale del Delta, Azienda USL of Ferrara, University of Ferrara, Via Valle Oppio 2, Lagosanto (FE), Ferrara 44023, Italy. antonio.pesce@ausl.fe.it

Abstract

Laparoscopic cholecystectomy (LC) is one of the most frequently performed gastrointestinal surgeries worldwide. Bile duct injury (BDI) represents the most serious complication of LC, with an incidence of 0.3%-0.7%, resulting in significant perioperative morbidity and mortality, impaired quality of life, and high rates of subsequent medico-legal litigation. In most cases, the primary cause of BDI is the misinterpretation of biliary anatomy, leading to unexpected biliary lesions. Near-infrared fluorescent cholangiography is widely spreading in clinical practice to delineate biliary anatomy during LC in elective and emergency settings. The primary aim of this article was to perform an up-to-date overview of the evolution of this method 12 years after the first clinical application in 2009 and to highlight all advantages and current limitations according to the available scientific evidence.

Key Words: Laparoscopic cholecystectomy; Bile duct injury; Biliary anatomy; Fluorescent cholangiography; Indocyanine green

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Fluorescence image-guided surgery is one of the most recent innovations in

s/by-nc/4.0/

Manuscript source: Invited manuscript**Specialty type:** Gastroenterology and hepatology**Country/Territory of origin:** Italy**Peer-review report's scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

Received: April 15, 2021**Peer-review started:** April 15, 2021**First decision:** July 1, 2021**Revised:** July 10, 2021**Accepted:** August 30, 2021**Article in press:** August 30, 2021**Published online:** September 28, 2021**P-Reviewer:** Ghannam WM, Grosek J, Komatsu S, Wang SY**S-Editor:** Wang LL**L-Editor:** A**P-Editor:** Xing YX

laparoscopic and robotic surgery. The visualization of biliary anatomy using fluorescence during surgery is becoming one of the most promising frontier approaches in minimally invasive surgery. This novel method is a powerful tool to detect biliary variants that could guide surgeons during dissection to prevent major bile duct lesions, and it has enormous potential to be considered the gold standard during all cholecystectomies. The up-to-date overview of this method confirms the efficacy of indocyanine green fluorescence cholangiography in detecting biliary anatomy, its importance as a teaching tool for young surgeons, and the effects on the reduction of conversion rate and bile duct injury, even if further considerable research remains necessary to optimize its use.

Citation: Pesce A, Piccolo G, Lecchi F, Fabbri N, Diana M, Feo CV. Fluorescent cholangiography: An up-to-date overview twelve years after the first clinical application. *World J Gastroenterol* 2021; 27(36): 5989-6003

URL: <https://www.wjgnet.com/1007-9327/full/v27/i36/5989.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v27.i36.5989>

INTRODUCTION

Laparoscopic cholecystectomy (LC) is one of the most frequently performed gastrointestinal surgeries worldwide. Bile duct injury (BDI) represents the most serious complication of LC, with an incidence of 0.3% to 0.7%, resulting in significant perioperative morbidity and mortality, impaired quality of life, and high rates of subsequent medico-legal litigation[1,2]. In most cases, the primary cause of BDI is the misinterpretation of biliary anatomy, leading surgeons to unexpected biliary lesions (71%-97% of all cases)[3,4]. Various methods have been proposed and used to prevent iatrogenic biliary tract lesions[4]. Among them, near-infrared fluorescent cholangiography (NIRF-C) is widely spreading in clinical practice to delineate biliary anatomy during LC in elective and emergency settings. It is becoming one of the most popular and promising clinical applications in minimally invasive surgery[5,6]. In 2006, Stiles BM *et al*[7] first proposed fluorescent cholangiography in a mouse model by exploiting the unique auto fluorescent properties of bile for the intraoperative identification of the biliary anatomy in mice. The first application in humans was performed and described by Ishizawa *et al*[8] a few years later (2009). This classical method involves the intravenous injection of indocyanine green (ICG) dye before surgery. ICG binds to plasma proteins, with albumin as the principal carrier (95%), and is eliminated exclusively by the liver. The excitation of ICG by means of near-infrared light causes fluorescence, thereby delineating the anatomy of the biliary elements in real time. This innovative method was introduced as a means to prevent bile duct injuries during LC due to a better visualization of biliary anatomy during dissection. In 2015, we performed a systematic review of available studies by analyzing the efficacy of the novel technique in detecting bile duct structures during surgery. Detection rates of the biliary anatomy in 590 pooled patients were as follows: Cystic duct (CD) 96.2% (94.7%-97.7%), common hepatic duct (CHD) 78.1% (74.8%-81.4%), CD-CHD junction 72.0% (69.0%-75.0%), and common bile duct (CBD) 86.0% (83.3%-88.8%)[9]. Overall, these preliminary studies indicated that ICG fluorescence cholangiography is highly sensitive for the detection of extrahepatic biliary anatomy and may facilitate the prevention of bile duct injuries. Over the years, several single-center experiences from different countries[10-12] have been published regarding the usefulness of ICG fluorescence cholangiography in detecting biliary anatomy and analyzing patient outcomes after LC. The level of scientific evidence on ICG fluorescence cholangiography remains low. However, recent studies have significantly propelled the literature forward.

The primary aim of this article was to perform an up-to-date overview of the evolution of this method 12 years after its first clinical application and to highlight all the advantages and current limitations according to the available scientific literature.

TECHNIQUES

ICG administration can be performed in two different ways. The classical method described by Ishizawa T *et al*[8] in 2009 consists of the intravenous injection of ICG 30 min before surgery. Biliary visualization should be obtained prior to any dissection, during the dissection of the hepatocystic triangle, and after complete dissection according to the critical view of safety (CVS) method[13,14]. This approach enables surgeons to check the biliary anatomy intraoperatively at any time. Recently, Dip F *et al*[15] summarized 10 important steps for the correct performance of fluorescent cholangiography during LC. The first two steps involve ICG intravenous administration and complete exposure of the hepatoduodenal ligament prior to any dissection. The primary objective of step 3 is the localization of the main biliary structures after the partial dissection of the hepatocystic triangle. Steps 4-7 are characterized by the identification of the CD, gallbladder-CD junction, CD-CHD junction, and CBD; step 8 is the identification of the cystic artery, in some cases by repeating ICG injection for fluorescent angiography to detect any anatomical arterial variations; step 9 is called “time-out”, and it consists of the re-evaluation of the CVS before clipping and cutting any structures (as shown in Figures 1-2). After completing gallbladder removal, near-infrared (NIR) light should be turned on to identify any potential biliary leaks from the liver bed (step 10). At the current stage, there are two unresolved issues regarding NIRF-C, *i.e.*, the dose and the time required to obtain an optimal bile duct-to-liver fluorescence ratio >1. An elevated background liver signal may hinder the correct visualization of biliary anatomy. The dose and the time of administration of ICG are quite variable, as reported in the literature[16]. A recent study with data from the European Fluorescence Image-Guided Surgery (FIGS) registry[17] has shown a wide disparity in ICG dose and timing in NIRF-C across different European countries. Boogerd L *et al*[18] demonstrated that the highest bile duct-to-liver ratio was achieved 3 to 7 h after administration of 5 mg of ICG and 5 to 25 h after administration of 10 mg of ICG. Another study by Zarrinpar A *et al*[19] confirmed that a single dose of 0.25 mg/kg administered at least 45 min prior to visualization of the hepatocystic triangle facilitates intra-operative anatomical identification. Recently, Chen Q *et al*[20] demonstrated that the optimal effect of fluorescent cholangiography can be achieved by injecting 10 mg of ICG 10 to 12 h prior to surgery. Matsumura M *et al*[21] recommended the administration of 0.25 mg/kg ICG on the evening before surgery, as it may increase bile duct detectability in fluorescence cholangiography during LC. Based on our experience, we think that the administration of ICG 45 to 60 min before surgery is—from a logistical point of view - more practical since most patients are usually hospitalized on the same day as the surgical procedure. Indeed, the debate remains open, and a consensus conference may help the surgical community.

The direct injection of ICG into the gallbladder is a technique that allows overcoming the strong background signal in the liver. Liu YY *et al*[22] were the first to describe intracholecystic ICG administration during LC in a porcine model, proving the feasibility and usefulness of this technique to achieve adequate CVS. Few clinical studies of NIR cholecystocholangiography with direct ICG injection into the gallbladder were conducted, namely, two case reports, one case-control study, and a few prospective cohort studies, for a total of 80 patients, of whom 49 underwent surgery for symptomatic cholelithiasis and 31 for acute cholecystitis[22-26], as summarized in Table 1.

Liu YY *et al*[22] and Škrabec C *et al*[23] conducted the two widest studies, namely, a prospective cohort study of 46 patients and a case-control study including 20 patients, respectively. The authors described two different routes for intracholecystic ICG injection, *i.e.*, percutaneous transhepatic gallbladder drainage (trans-PTGBD) and intra-operative direct gallbladder puncture. A 1 mL amount of an ICG bile solution was used (ICG concentration = 0.025 mg/mL) made from a combination of 9 mL of bile mixed with 1 mL of a preparation of ICG and sterile water at a concentration of 0.25 mg/mL. NIR cholecystocholangiography with direct gallbladder injection was more successful in acute cholecystitis patients who underwent early or interval LC after the preliminary positioning of a PTGBD. Among all cases reported in the literature, only one patient required conversion to open cholecystectomy due to acute necrotic cholecystitis, which precluded safe laparoscopic dissection.

Intracholecystic ICG injection provides relevant advantages compared to intravenous NIR cholecystocholangiography, such as the real-time visualization of the biliary anatomy, including the gallbladder neck and Hartmann’s pouch, which are safe landmarks to start the dissection. Additionally, the timing of ICG injection is irrelevant, and small dosages can be used.

Table 1 Cholecysto-cholangiography with direct intra-gallbladder indocyanine green injection

Ref.	Type of publication	No. of patients	No. of patients with gallbladder lithiasis	No. of patients with acute cholecystitis	Technique	Complication	Conversion to open surgery
Jao <i>et al</i> [26], 2020	Case series	2	0	2	2 trans-PTGBD cases	Lymphatic spillage	0
Nitta <i>et al</i> [24], 2020	Case report	1	0	1	1 case through DGBP	-	0
Škrabec <i>et al</i> [23], 2020	Case-controlled study	20	19	1	20 cases through DGBP	ICG bile leakage in 1 case; No progression of dye into the CD in 3 cases	1
Liu <i>et al</i> [22], 2017	Cohort study	46	21	25	18 trans-PTGBD cases; 28 cases through DGBP	ICG leakage in 5 cases	0
Graves <i>et al</i> [25], 2017	Cohort study	11	9	2	11 cases through DGBP	No progression of dye into the CD in 1 case	0

PTGBD: Percutaneous transhepatic gallbladder drainage; DGBP: Direct gallbladder puncture; ICG: Indocyanine green; CD: Cystic duct.




Figure 1 Intra-operative real-time identification of biliary structures in a cirrhotic patient, with visible light to the left and NIRF-C to the right. A: Pre-dissection visualization of biliary anatomy; B: After complete dissection. One can observe the posterior implantation of the cystic duct on the common hepatic duct. CD: Cystic duct; CHD: Common hepatic duct; CBD: Common bile duct.

The downside of direct ICG injection lies in the possibility of ICG bile leakage or lymph spillage during gallbladder dissection for acute cholecystitis, as ICG may enter through the necrotic gallbladder mucosa into the submucosal lymphatic drainage. In regard to the widest experiences reported in the literature[22,23], ICG bile leakage occurred in six patients in whom ICG was directly injected through a fine-needle puncture. Another limitation lies in the absence of progression of the dye into the CD




Figure 2 Classical extrahepatic biliary anatomy with identification of the right and left hepatic ducts using near-infrared fluorescent cholangiography. CD: Cystic duct; CHD: Common hepatic duct; RHD: Right hepatic duct; LHD: Left hepatic duct.

in cases of stone obstruction.

Based on the available data, we suggest that larger studies are necessary to validate the technique of intracholecystic ICG injection for NIR fluorescent cholangiography.

ICG FLUORESCENT CHOLANGIOGRAPHY IN PATIENTS WITH ACUTE CHOLECYSTITIS

Early LC is the gold standard treatment for patients with mild (grade I) and moderate (grade II) acute cholecystitis who have no response to initial (within 24 h) conservative treatment if performed within 72 h from the onset of symptoms according to 2018 Tokyo guidelines[27].

Fluorescent cholangiography may be very challenging in an emergency setting, when inflammation and adhesions at the hepatoduodenal ligament may impair the identification of biliary elements during dissection. Reaching the CVS may be particularly difficult in such situations[28].

In a recent meta-analysis, Dip F *et al*[29] suggested that using NIRF-C during elective cholecystectomy led to decreased BDI and conversion to open surgery compared to white light alone. However, there are limited data about its feasibility in an emergency setting. The identification of biliary structures may be challenging, especially in cases where there is an abundance of adhesions and severe inflammation of the gallbladder wall and surrounding tissues[9].

The literature contains four articles that provide data of patients who underwent LC for acute cholecystitis with NIR devices, *i.e.*, two cohort studies[30,31], one international European registry[17], and one randomized controlled trial (RCT)[32] are reported in Table 2.

In a large retrospective study involving 184 consecutive patients, Daskalaki E *et al* [31] reported the results of 24 patients who underwent robotic cholecystectomies (RCs) with ICG fluorescence for acute and gangrenous cholecystitis. The authors evaluated the detection rate of four biliary structures, *i.e.*, CD, CHD, CBD, and CD-CHD junction. In this subset of challenging surgical cases, the CD, CHD, CBD, and CD-CHD junction were successfully visualized in 91.6%, 79.1%, 79.1%, and 75% of cases, respectively.

Agnus V *et al*[17] reported data from the Euro-FIGS database, which enrolled 314 cases from 12 European surgical centers, including patients affected by symptomatic cholelithiasis ($n = 248$) and patients with acute cholecystitis ($n = 58$). A 5-point Likert scale was used to evaluate the quality of biliary anatomy visualization before and after the dissection of the hepatocystic triangle during LC with NIR devices. When the two groups (cholelithiasis *vs* acute cholecystitis) were compared, lower visualization quality scores were obtained in the CD group (2.76 ± 1.9 *vs* 3.54 ± 1.6 , $P = 0.001$) and CD-CHD junction (2.43 ± 2 *vs* 3 ± 1.9 , $P = 0.04$) before the preliminary dissection. The impact of variable inflammation on the visualization score of the biliary tree was also confirmed by means of multivariate linear regression analysis.

Table 2 Fluorescent cholangiography in patients with acute cholecystitis

Ref.	Type of publication	Procedure	No. of patients
Agnus <i>et al</i> [17], 2020	Euro-FIGS registry	LC	58
Dip <i>et al</i> [32], 2020	RCT	LC	44
Di Maggio <i>et al</i> [30], 2020	Prospective cohort study	LC	16
Daskalaki <i>et al</i> [31], 2014	Retrospective cohort study	RC	24
Yoshiya <i>et al</i> [33], 2019	Retrospective cohort study	LC after-PTGBD	130

FIGS: Fluorescence image-guided surgery; RCT: Randomized controlled trial; LC: Laparoscopic cholecystectomy; RC: Robotic cholecystectomy; PTGBD: Percutaneous transhepatic gallbladder drainage.

Similar data have been reported in a single-blinded randomized controlled trial[32] comparing the efficacy of NIR fluorescent cholangiography *vs* white light alone. The primary objective was the structure detection rate, defined as the total number of patients in whom a particular biliary structure was detected, both before and after dissection, in each study arm, divided by the total number of patients in each arm. The authors found that the degree of gallbladder inflammation was the most important variable, affecting the detection of CD and CBD before and after dissection, respectively, and of the CD-gallbladder junction only after dissection.

The usefulness of NIRF-C was also confirmed by Yoshiya S *et al*[33] during LC after PTGBD in patients with severe acute cholecystitis. The ICG fluorescence cholangiography group showed a significantly shorter operative time, a lower conversion rate, and a lower proportion of subtotal cholecystectomies[33].

NIR fluorescence cholangiography in emergency cholecystectomies is a safe and useful tool to prevent BDI during LC. However, the available data require further elaboration in randomized controlled studies in larger numbers of patients with acute cholecystitis undergoing LC with the aid of intra-operative fluorescent cholangiography.

DETECTION OF BILIARY VARIANTS USING ICG FLUORESCENCE

Various reports have underlined the importance of fluorescence image-guided cholecystectomy in detecting biliary variants. Fluorescent cholangiography allows the intraoperative identification of subvesical Luschka's ducts[34,35], aberrant bile ducts [36-38], anatomical CD variations[39], and gallbladder aberrations[40,41].

In specific studies, the diagnostic accuracy of NIRF-C in the evaluation of CD anatomy has been compared to that of magnetic resonance cholangiopancreatography (MRCP), which is the gold standard radiology diagnostic tool for the preoperative study of the biliary tree[42,43]. Pesce A *et al*[44] evaluated the ability of the two imaging methods to identify three selected features, namely, the insertion of CD, CD-CHD junction, and CD course. The level of insertion, course, and wall implantation of the CD were achieved by means of NIRF-C with diagnostic accuracy values of 65.2%, 78.3%, and 91.3%, respectively, in comparison with MRCP data.

In 2017, Diana M *et al*[45] prospectively evaluated the combination of three imaging modalities during robotic cholecystectomy, *i.e.*, virtual reality 3D modeling of MRCP, NIRF-C, and intraoperative cholangiogram (IOC). Surprisingly, expert hepatobiliary radiologists missed 5 out of 8 anatomical variants on preoperative MRCP, while surgeons were able to identify all variants through a virtual surgical exploration complemented with intraoperative fluorescent cholangiography.

In another observational study in 65 patients by Hiwatashi K *et al*[46], the authors found a statistically significant correlation between the delineation of CD using ICG cholangiography and preoperative MRCP.

Based on the current scientific literature (RCTs shown in Table 3), we strongly believe that NIRF-C is a useful tool to detect biliary variants that could guide surgeons during dissection to prevent any major bile duct lesions.

Table 3 Recruiting randomized controlled trials using indocyanine green fluorescence cholangiography

Study coordinator; NCT No.	Participating country	No. of patients	Period study	Published data	Main outcome	Controlled group	Dose indocyanine green	Dosing time	Conversion to open surgery	Bile duct injury
Dip <i>et al</i> [32]; NCT 02702843	United States	639	April 2016	<i>Ann Surg</i> 2020	Identification of biliary anatomy	White light	0.05 mg/kg	> 45 min prior to surgery	One patient for bleeding	No
Lehrskov <i>et al</i> [50]; NCT 02344654	Denmark	120	March 2015-August 2018	<i>Br J Surg</i> 2020	Visualization of the critical junction	Intraoperative cholangiogram	0.05 mg/kg	After intubation	No	No
van den Bos <i>et al</i> [61]; NCT 02558556	The Netherlands	308	January 2016	Ongoing	Time to achieve critical view of safety	White light	2.5 mg	After intubation	NA	NA
Koong <i>et al</i> [60]; NCT04228835	Malaysia	63	March 2017-July 2019	<i>Asian J Surg</i> 2021	Time to achieve critical view of safety	White light	2.5 mg	Before induction of anesthesia	No	No

NA: Not available.

FLUORESCENT CHOLANGIOGRAPHY VS STANDARD INTRAOPERATIVE CHOLANGIOGRAPHY

NIRF-C has been recognized as providing some advantages over conventional radiographic IOC, such as feasibility and safety, real-time visualization of biliary anatomy with safer dissection of the hepatocystic triangle, the lack of a learning curve, reduced X-ray exposure, and reduced costs and operative times[5,47-49]. In a Danish randomized controlled single-blind clinical trial[50], the authors compared NIRF-C *vs* IOC. They demonstrated that fluorescent cholangiography has the same capacity to identify the CVS, and is significantly faster and easier to perform than X-ray cholangiography[50]. In a recent meta-analysis by Lim SH *et al*[51], the authors concluded that there was no difference in the visualization of the CD, CBD, and CD-CBD junction using ICG fluorescence cholangiography compared to IOC. However, the ICG group reported increased rates of CHD visualization.

Dip F *et al*[52] analyzed medical costs and stated that the median cost of ICG fluorescence cholangiography was cheaper than that of IOC (13.97 ± 4.3 *vs* 778.43 ± 0.4 USD per patient, $P = 0.0001$).

Quaresima S *et al*[53] proposed that NIRF-C is a safe and effective procedure for the early recognition of anatomical biliary landmarks, with an important reduction in operative times compared to LC with intraoperative cholangiography.

In an article by Prevot F *et al*[54], the authors analyzed the ability to identify the CD, the CD-hepatic duct junction, and the CBD using fluorescence in comparison with standard IOC. The results of this study suggested that ICG fluorescence cholangiography is more effective than IOC in identifying the biliary tract after dissection.

In conclusion, we believe that there is considerable scientific evidence supporting the usefulness of NIRF-C with important advantages over conventional intraoperative cholangiography. NIRF-C represents a powerful real-time diagnostic tool for the detection of extrahepatic biliary anatomy during LC. Advantages and current limitations are summarized in Table 4.

FLUORESCENT CHOLANGIOGRAPHY IN OBESE PATIENTS

As reported in previous studies[9,31,55-57], the presence of dense adipose tissue surrounding the hepatocystic triangle may negatively affect the visualization of extrahepatic biliary tract using fluorescence. Obesity may represent a limitation of NIRF-C because NIR light has a penetration capability of only 5 to 10 mm[7-9]. In 2016, Dip F *et al*[58] conducted a prospective study to evaluate the accuracy of NIRF-C in obese *vs* non-obese patients. The results showed no difference in hepatic duct, CBD, or accessory duct detection rates between the two groups ($P = 0.09$, 0.16 , and 0.66 ,

Table 4 Advantages and current limitations of fluorescent cholangiography in comparison to intraoperative cholangiogram and laparoscopic ultrasonography

Advantages	Limitations
Real-time visualization of biliary anatomy in elective and emergent settings	Limited in patients with specific conditions, such as overweight and obesity; it needs a preliminary dissection and exposure of the hepatocystic triangle
Safer dissection of the hepatocystic triangle	Limited scientific evidence in the setting of acute cholecystitis
Detection of biliary variants and biliary leaks	High variability about indocyanine green dose and dosing time
Implementing method in combination with adequate dissection and identification technique to achieve critical view of safety	Detection of bile duct stones
Feasibility and safety	Need for consensus conference and international guidelines
Reduced medical costs	
Time/faster	
Lack of X-ray exposure	
Simplicity and lack of learning curve	
Teaching tool for young surgeons	
Possibility to associate fluorescent angiography	
Strong potential to become a gold standard during all cholecystectomies	

respectively) before and after dissection of the hepatocystic triangle.

On the other hand, a German study[59] suggested that a BMI > 25 kg/m² and male sex significantly reduced the identification rate of CD before dissection of the hepatocystic triangle.

In a randomized controlled multicenter trial[32] comparing ICG *vs* white light alone, an increased BMI was associated with a reduced detection of most biliary structures in both groups, especially before dissection.

In general, our opinion is to use fluorescence to perform a complete dissection of the hepatocystic triangle in overweight and obese patients to obtain a good quality visualization of the biliary anatomy. In difficult cases where the surgeon is not able to clearly check the biliary anatomy, the surgeon should respect a sufficient thickness between the dissecting site and the main bile duct by working close to the gallbladder infundibulum to avoid unexpected biliary lesions. NIR imaging cannot be considered a substitute for good dissection and structure identification.

FLUORESCENT INCISIONLESS CHOLANGIOGRAPHY AS A TEACHING TOOL FOR YOUNG SURGEONS

It is well established that the risk of BDI correlates with the quality of the procedure performed, rather than the number of cases seen by the surgeon[1,2]. A clear identification of the biliary anatomy is crucial to perform a safe cholecystectomy and achieving CVS is now being taught as a key step of the operation to young surgeons[4, 13]. In a recent randomized controlled trial[60], the time to achieve CVS from the gallbladder fundus retraction was measured by analyzing different levels of difficulty. The mean time, expressed in minutes, to achieve CVS was 22.3 ± 12.9 in the ICG-LC group (*n* = 30) and 22.8 ± 14.3 in the conventional LC group (*P* = 0.867). The authors concluded that fluorescent cholangiography may be a useful tool in difficult LC and in surgical training. A randomized controlled multicenter Dutch trial (FALCON trial) regarding the time to visualize CVS with NIRF-C compared to white light alone is still ongoing[61]. However, biliary structures are not always easily visualized laparoscopically. Fluorescence incisionless cholangiography may be a promising tool for training new surgeons in safe laparoscopic cholecystectomies by helping with biliary anatomy identification. To date, few studies have been conducted regarding the potential role of this technique in surgical training programs[62-64].

In 2016, Roy M *et al*[62] tested the ability of surgical students and residents to identify major biliary structures at NIR light. Participants were shown pictures taken at the same stage of hepatocystic triangle dissection in 10 cases of LC, first with NIR

light and then with Xenon white light. Both students and residents had a higher success rate of biliary tree identification with NIR fluorescence cholangiography. The authors also underlined the importance of NIRF-C to achieve appropriate intraoperative communication to guide residents, as it allows us to point out glowing structures in real time.

Similarly, in 2020, Rungsakulkij N *et al*[63] conducted a study to investigate the beneficial impact of fluorescence cholangiography on the ability of surgical residents to identify biliary structures. Participants were asked to identify the CD and artery, CBD and CHD in five LC videos, first without fluorescence, and then with NIRF-C. The results showed a higher misidentification rate among surgical residents in the without-FC modality than in the with-FC modality, proving the benefit of the technique among trainees.

In a study by Pesce A *et al*[47] on the usefulness of fluorescent cholangiography for biliary anatomy identification, surgical residents completed a survey on the perceived benefits of the technique. Responses were measured with a Likert scale. All participants agreed that NIRF-C facilitates the dissection of the hepatocystic triangle, hence being a useful adjuvant to training programs; 92% of respondents found the method easy to perform; 88% declared that it was effective in visualizing the biliary tree, and 84% found that the image quality was good. Consequently, residents consider the novel method a useful tool to visualize biliary anatomy and perform a safe dissection of the hepatocystic triangle, decreasing the risk of BDI.

From these experiences, it is safe to conclude that there is a large consensus regarding the beneficial role of NIRF-C in the training process of young surgeons. However, larger studies proving the benefits on the skills of surgical residents are required for the technique to be routinely performed in a teaching setting.

FLUORESCENT CHOLANGIOGRAPHY AND DETECTION OF BILIARY STONES

To date, there is no evidence that FC can effectively identify CBD stones by replacing IOC[64,65]. Intraoperative laparoscopic ultrasound (IOUS) could well represent a valid alternative to IOC in the detection of CBD stones[66,67]. Current limitations are related to the difficult learning curve and the lack of randomized controlled trials[66]. According to Daskalaki M *et al*[27], ICG fluorescence cholangiography can help to detect CD dilation and gallbladder stones (as shown in Figure 3), but it cannot rule out the presence of CBD stones. In a recent correspondence by Labil PL and Aroori S published in *Br J Surg*[65], the authors suggested performing an RCT comparing IOUS with X-ray and/or fluorescence cholangiography in LC to detect a difference in the rate of bile duct stone identification, as well as viewing the critical junction.

NIRF-C AND ROBOTIC CHOLECYSTECTOMY

Since the introduction of the robotic surgical platform in the 2000s, approximately 10% of all cholecystectomies are performed robotically[68] today. ICG technology was soon incorporated into the robotic platform, and the first case series involved patients who underwent single-incision or multiport robotic cholecystectomy (RC) with NIRF-C, as summarized in Table 5.

In a large retrospective cohort study including 184 patients, Daskalaki D *et al*[31] proved the feasibility of this technique. The four main biliary structures (CD, CHD, CD-CHD junction, CBD) were recognized using fluorescence imaging in 83% of cases. At least one structure was visualized in 99% of cases. Similar data have been reported by other authors[55,69-71].

Spinoglio G *et al*[70] showed that after dissection of the hepatocystic triangle, the visualization rates for each structure (CD, CHD, CD-CHD junction, CBD) increased to 97%. In addition, the rate of patients with two or three ducts visualized with NIR fluorescent cholangiography increased from 91% to 97% and from 86% to 95% before and after dissection, respectively.

In recent years, some authors compared data of patients who underwent robotic cholecystectomy with the use of ICG *vs* conventional LC[72,73]. In a retrospective cohort study, Sharma S *et al*[72] analyzed 287 consecutive cases, including 96 RCs and 191 LCs. The authors found a lower open conversion rate in the robotic cohort (2.1% *vs* 8.9% in LC), although this difference was not statistically significant.

Table 5 Studies reporting robotic cholecystectomy and near-infrared fluorescent cholangiography

Ref.	Type of publication	No. of patients	Technique	Incidence of conversion rate to open surgery (%)
Sharma <i>et al</i> [72], 2017	Retrospective cohort study	96	RC	2.1
Gangemi <i>et al</i> [73], 2017	Retrospective cohort study	676	RC	0.15
Maker <i>et al</i> [71], 2017	Cohort study	35	RC	NR
Daskalaki <i>et al</i> [31], 2014	Retrospective cohort study	184	RC	0.00
Spinoglio <i>et al</i> [70], 2013	Cohort study	45	SIRC	0.00
Buchs <i>et al</i> [55], 2013	Cohort study	23	SIRC	0.00
Buchs <i>et al</i> [69], 2012	Prospective cohort study	12	SIRC	0.00

RC: Robotic cholecystectomy; SIRC: Single-incision robotic cholecystectomy; NR: Not reported.




Figure 3 Identification of cystic duct stones by means of fluorescence.

Gangemi A *et al*[73] conducted a case-control study comparing the outcomes of ICG-aided RC *vs* LC at the University of Illinois (Chicago, United States). The authors reported a statistically significant difference between RC performed with the help of ICG and traditional LC in terms of the overall open conversion rate (0.15% *vs* 4.5%), open conversion rate in the acute setting (0.76% *vs* 9.57%), mean blood loss during surgery (14.37 mL *vs* 21.08 mL), and minor biliary injury rate (0.15% *vs* 1.04%). Additionally, a biliary tree anomaly was found in 2.07% of patients who underwent ICG-aided RC compared to 0.69% of patients who underwent LC with conventional intraoperative cholangiography.

Recently, Dip *et al*[29] conducted a meta-analysis evaluating whether NIFC with ICG could reduce conversion to open surgery and bile duct injuries during laparoscopic and robotic cholecystectomy. Patients who underwent ICG-aided RC showed a marked reduction in the rate of conversion to open surgery compared to RC without NIFC (weighted rate: 12/10,000 *vs* 322/10,000). Similar data were reported in the ICG-aided LC group (weighted rate: 23/10,000 *vs* 255/10,000). For BDI, a reduction was reported in the ICG-aided LC group compared to LC without NIFC (weighted rate: 23/10,000 *vs* 255/10,000), while no difference was noted regarding RC with and without NIFC. In conclusion, we believe that the use of NIRF-C may reduce the conversion rate in both minimally invasive procedures, laparoscopic and robotic cholecystectomy, while the reduction rate only exists in LC for BDI. However, further studies are required.

CONSENSUS CONFERENCES AND GUIDELINES

During the 4th International Congress of Fluorescence-Guided Surgery in Boca Raton, Florida in 2017, Dip F *et al*[74] conducted a pilot survey of 51 attending surgeons who

routinely performed laparoscopic cholecystectomies to identify their surgical practice and perceptions of intraoperative fluorescent cholangiography. Ten experts in ICG fluorescence-guided LC from North and South America, Europe, and Asia designed the survey for conference attendees. Seventy-eight percent of respondents underlined the importance for surgeons of having a noninvasive, simple, and reproducible diagnostic tool to identify the extrahepatic biliary anatomy in real time. In general, they recommended the routine use of NIRF-C during LC as a complimentary imaging technique, and 93.3% of them felt that the procedure would be useful in surgical training programs.

In a recent state-of-the-art consensus conference on the prevention of BDI during cholecystectomy published in *Annals of Surgery*[75], a pool of experts from five surgical societies (Society of Gastrointestinal and Endoscopic Surgeons, Americas Hepato-Pancreato-Biliary Association, International Hepato-Pancreato-Biliary Association, Society for Surgery of the Alimentary Tract, and European Association for Endoscopic Surgery) analyzed the scientific evidence among surgical practices to prevent bile duct injuries. At question 5B, *i.e.*, “Should intraoperative NIR biliary imaging with white light versus white light biliary imaging alone be used to limit the risk or severity of BDI during LC?”, they answered the following question: We suggest that the use of NIR imaging may be considered an adjunct to white light alone to identify the biliary anatomy during cholecystectomy (conditional recommendation, very low certainty of evidence).

However, in a Delphi survey of 19 international experts in fluorescence-guided surgery attending a 1 d consensus meeting in Frankfurt, Germany in September 2019, fluorescence imaging was almost unanimously perceived to be both effective and safe across a broad range of clinical settings[76]. No specific recommendations were given for fluorescent cholangiography. Moreover, the safety of ICG dye has been underlined: the risk of adverse reactions to ICG injection, such as anaphylactic shock, is very small (approximately 0.003% at doses exceeding 0.5 mg/kg) according to the literature data [9,77].

CONCLUSION

The results of the current up-to-date overview confirmed the efficacy of ICG-fluorescence cholangiography in detecting biliary anatomy, its importance as a teaching tool for young surgeons, and the effects on the reduction of conversion rate and BDI, even if further considerable research remains necessary to optimize its use. This frontier method has enormous potential to become the gold standard during all cholecystectomies in elective and emergency settings due to its safety and limited costs. However, clear clinical guidelines are necessary for the surgical community.

REFERENCES

- 1 Nuzzo G, Giuliani F, Giovannini I, Ardito F, D'Acapito F, Vellone M, Murazio M, Capelli G. Bile duct injury during laparoscopic cholecystectomy: results of an Italian national survey on 56 591 cholecystectomies. *Arch Surg* 2005; **140**: 986-992 [PMID: 16230550 DOI: 10.1001/archsurg.140.10.986]
- 2 Way LW, Stewart L, Gantert W, Liu K, Lee CM, Whang K, Hunter JG. Causes and prevention of laparoscopic bile duct injuries: analysis of 252 cases from a human factors and cognitive psychology perspective. *Ann Surg* 2003; **237**: 460-469 [PMID: 12677139 DOI: 10.1097/01.SLA.0000060680.92690.E9]
- 3 Pesce A, Portale TR, Minutolo V, Scilletta R, Li Destri G, Puleo S. Bile duct injury during laparoscopic cholecystectomy without intraoperative cholangiography: a retrospective study on 1,100 selected patients. *Dig Surg* 2012; **29**: 310-314 [PMID: 22986956 DOI: 10.1159/000341660]
- 4 Pesce A, Palmucci S, La Greca G, Puleo S. Iatrogenic bile duct injury: impact and management challenges. *Clin Exp Gastroenterol* 2019; **12**: 121-128 [PMID: 30881079 DOI: 10.2147/CEG.S169492]
- 5 Majlesara A, Golriz M, Hafezi M, Saffari A, Stenau E, Maier-Hein L, Müller-Stich BP, Mehrabi A. Indocyanine green fluorescence imaging in hepatobiliary surgery. *Photodiagnosis Photodyn Ther* 2017; **17**: 208-215 [PMID: 28017834 DOI: 10.1016/j.pdpdt.2016.12.005]
- 6 Baiocchi GL, Diana M, Boni L. Indocyanine green-based fluorescence imaging in visceral and hepatobiliary and pancreatic surgery: State of the art and future directions. *World J Gastroenterol* 2018; **24**: 2921-2930 [PMID: 30038461 DOI: 10.3748/wjg.v24.i27.2921]
- 7 Stiles BM, Adusumilli PS, Bhargava A, Fong Y. Fluorescent cholangiography in a mouse model: an innovative method for improved laparoscopic identification of the biliary anatomy. *Surg Endosc*

- 2006; **20**: 1291-1295 [PMID: [16858526](#) DOI: [10.1007/s00464-005-0664-x](#)]
- 8 **Ishizawa T**, Tamura S, Masuda K, Aoki T, Hasegawa K, Imamura H, Beck Y, Kokudo N. Intraoperative fluorescent cholangiography using indocyanine green: a biliary road map for safe surgery. *J Am Coll Surg* 2009; **208**: e1-e4 [PMID: [19228492](#) DOI: [10.1016/j.jamcollsurg.2008.09.024](#)]
- 9 **Pesce A**, Piccolo G, La Greca G, Puleo S. Utility of fluorescent cholangiography during laparoscopic cholecystectomy: A systematic review. *World J Gastroenterol* 2015; **21**: 7877-7883 [PMID: [26167088](#) DOI: [10.3748/wjg.v21.i25.7877](#)]
- 10 **Igami T**, Nojiri M, Shinohara K, Ebata T, Yokoyama Y, Sugawara G, Mizuno T, Yamaguchi J, Nagino M. Clinical value and pitfalls of fluorescent cholangiography during single-incision laparoscopic cholecystectomy. *Surg Today* 2016; **46**: 1443-1450 [PMID: [27002714](#) DOI: [10.1007/s00595-016-1330-8](#)]
- 11 **Broderick RC**, Lee AM, Cheverie JN, Zhao B, Blitzer RR, Patel RJ, Soltero S, Sandler BJ, Jacobsen GR, Doucet JJ, Horgan S. Fluorescent cholangiography significantly improves patient outcomes for laparoscopic cholecystectomy. *Surg Endosc* 2020 [PMID: [33052527](#) DOI: [10.1007/s00464-020-08045-x](#)]
- 12 **Bleszynski MS**, DeGirolamo KM, Meneghetti AT, Chiu CJ, Panton ON. Fluorescent Cholangiography in Laparoscopic Cholecystectomy: An Updated Canadian Experience. *Surg Innov* 2020; **27**: 38-43 [PMID: [31744398](#) DOI: [10.1177/1553350619885792](#)]
- 13 **Strasberg SM**, Brunt LM. Rationale and use of the critical view of safety in laparoscopic cholecystectomy. *J Am Coll Surg* 2010; **211**: 132-138 [PMID: [20610259](#) DOI: [10.1016/j.jamcollsurg.2010.02.053](#)]
- 14 **Ishizawa T**, Bandai Y, Ijichi M, Kaneko J, Hasegawa K, Kokudo N. Fluorescent cholangiography illuminating the biliary tree during laparoscopic cholecystectomy. *Br J Surg* 2010; **97**: 1369-1377 [PMID: [20623766](#) DOI: [10.1002/bjs.7125](#)]
- 15 **Dip F**, Aleman R, Frieder JS, Gomez CO, Menzo EL, Szomstein S, Rosenthal RJ. Understanding intraoperative fluorescent cholangiography: ten steps for an effective and successful procedure. *Surg Endosc* 2021 [PMID: [33475844](#) DOI: [10.1007/s00464-020-08219-7](#)]
- 16 **van den Bos J**, Wieringa FP, Bouvy ND, Stassen LPS. Optimizing the image of fluorescence cholangiography using ICG: a systematic review and ex vivo experiments. *Surg Endosc* 2018; **32**: 4820-4832 [PMID: [29777357](#) DOI: [10.1007/s00464-018-6233-x](#)]
- 17 **Agnus V**, Pesce A, Boni L, Van Den Bos J, Morales-Conde S, Paganini AM, Quaresima S, Balla A, La Greca G, Plaudis H, Moretto G, Castagnola M, Santi C, Casali L, Tartamella L, Saadi A, Picchetto A, Arezzo A, Marescaux J, Diana M. Fluorescence-based cholangiography: preliminary results from the IHU-IRCAD-EAES EURO-FIGS registry. *Surg Endosc* 2020; **34**: 3888-3896 [PMID: [31591654](#) DOI: [10.1007/s00464-019-07157-3](#)]
- 18 **Boogerd LSF**, Handgraaf HJM, Huurman VAL, Lam HD, Mieog JSD, van der Made WJ, van de Velde CJH, Vahrmeijer AL. The Best Approach for Laparoscopic Fluorescence Cholangiography: Overview of the Literature and Optimization of Dose and Dosing Time. *Surg Innov* 2017; **24**: 386-396 [PMID: [28457194](#) DOI: [10.1177/1553350617702311](#)]
- 19 **Zarrinpar A**, Dutson EP, Mobley C, Busuttil RW, Lewis CE, Tillou A, Cheaito A, Hines OJ, Agopian VG, Hiyama DT. Intraoperative Laparoscopic Near-Infrared Fluorescence Cholangiography to Facilitate Anatomical Identification: When to Give Indocyanine Green and How Much. *Surg Innov* 2016; **23**: 360-365 [PMID: [26964557](#) DOI: [10.1177/1553350616637671](#)]
- 20 **Chen Q**, Zhou R, Weng J, Lai Y, Liu H, Kuang J, Zhang S, Wu Z, Wang W, Gu W. Extrahepatic biliary tract visualization using near-infrared fluorescence imaging with indocyanine green: optimization of dose and dosing time. *Surg Endosc* 2020 [PMID: [33026517](#) DOI: [10.1007/s00464-020-08058-6](#)]
- 21 **Matsumura M**, Kawaguchi Y, Kobayashi Y, Kobayashi K, Ishizawa T, Akamatsu N, Kaneko J, Arita J, Kokudo N, Hasegawa K. Indocyanine green administration a day before surgery may increase bile duct detectability on fluorescence cholangiography during laparoscopic cholecystectomy. *J Hepatobiliary Pancreat Sci* 2021; **28**: 202-210 [PMID: [33091224](#) DOI: [10.1002/jhbp.855](#)]
- 22 **Liu YY**, Liao CH, Diana M, Wang SY, Kong SH, Yeh CN, Dallemagne B, Marescaux J, Yeh TS. Near-infrared cholecystocholangiography with direct intragallbladder indocyanine green injection: preliminary clinical results. *Surg Endosc* 2018; **32**: 1506-1514 [PMID: [28916859](#) DOI: [10.1007/s00464-017-5838-9](#)]
- 23 **Gené Škrabec C**, Pardo Aranda F, Espín F, Cremades M, Navinés J, Zárate A, Cugat E. Fluorescent cholangiography with direct injection of indocyanine green (ICG) into the gallbladder: a safety method to outline biliary anatomy. *Langenbecks Arch Surg* 2020; **405**: 827-832 [PMID: [32827267](#) DOI: [10.1007/s00423-020-01967-z](#)]
- 24 **Nitta T**, Kataoka J, Ohta M, Ueda Y, Senpuku S, Kurashima Y, Shimizu T, Ishibashi T. Laparoscopic cholecystectomy for cholecystitis using direct gallbladder indocyanine green injection fluorescence cholangiography: A case report. *Ann Med Surg (Lond)* 2020; **57**: 218-222 [PMID: [32793342](#) DOI: [10.1016/j.amsu.2020.07.057](#)]
- 25 **Graves C**, Ely S, Idowu O, Newton C, Kim S. Direct Gallbladder Indocyanine Green Injection Fluorescence Cholangiography During Laparoscopic Cholecystectomy. *J Laparoendosc Adv Surg Tech A* 2017; **27**: 1069-1073 [PMID: [28574801](#) DOI: [10.1089/lap.2017.0070](#)]
- 26 **Jao ML**, Wang YY, Wong HP, Bachhav S, Liu KC. Intracholecystic administration of indocyanine green for fluorescent cholangiography during laparoscopic cholecystectomy-A two-case report. *Int J*

- Surg Case Rep* 2020; **68**: 193-197 [PMID: [32172195](#) DOI: [10.1016/j.ijscr.2020.02.054](#)]
- 27 **Okamoto K**, Suzuki K, Takada T, Strasberg SM, Asbun HJ, Endo I, Iwashita Y, Hibi T, Pitt HA, Umezawa A, Asai K, Han HS, Hwang TL, Mori Y, Yoon YS, Huang WS, Belli G, Derveniz C, Yokoe M, Kiriya S, Itoi T, Jagannath P, Garden OJ, Miura F, Nakamura M, Horiguchi A, Wakabayashi G, Cherqui D, de Santibañes E, Shikata S, Noguchi Y, Ukai T, Higuchi R, Wada K, Honda G, Supe AN, Yoshida M, Mayumi T, Gouma DJ, Deziel DJ, Liau KH, Chen MF, Shibao K, Liu KH, Su CH, Chan ACW, Yoon DS, Choi IS, Jonas E, Chen XP, Fan ST, Ker CG, Giménez ME, Kitano S, Inomata M, Hirata K, Inui K, Sumiyama Y, Yamamoto M. Tokyo Guidelines 2018: flowchart for the management of acute cholecystitis. *J Hepatobiliary Pancreat Sci* 2018; **25**: 55-72 [PMID: [29045062](#) DOI: [10.1002/jhbp.516](#)]
 - 28 **Alander JT**, Kaartinen I, Laakso A, Pätälä T, Spillmann T, Tuchin VV, Venermo M, Välisuo P. A review of indocyanine green fluorescent imaging in surgery. *Int J Biomed Imaging* 2012; **2012**: 940585 [PMID: [22577366](#) DOI: [10.1155/2012/940585](#)]
 - 29 **Dip F**, Lo Menzo E, White KP, Rosenthal RJ. Does near-infrared fluorescent cholangiography with indocyanine green reduce bile duct injuries and conversions to open surgery during laparoscopic or robotic cholecystectomy? *Surgery* 2021; **169**: 859-867 [PMID: [33478756](#) DOI: [10.1016/j.surg.2020.12.008](#)]
 - 30 **Di Maggio F**, Hossain N, De Zanna A, Husain D, Bonomo L. Near-Infrared Fluorescence Cholangiography can be a Useful Adjunct during Emergency Cholecystectomies. *Surg Innov* 2020; **1553350620958562** [PMID: [32936054](#) DOI: [10.1177/1553350620958562](#)]
 - 31 **Daskalaki M**, Fernandes E, Wang X, Bianco FM, Elli EF, Ayloo S, Masrur M, Milone L, Giulianotti PC. Indocyanine green (ICG) fluorescent cholangiography during robotic cholecystectomy: results of 184 consecutive cases in a single institution. *Surg Innov* 2014; **21**: 615-621 [PMID: [24616013](#) DOI: [10.1177/1553350614524839](#)]
 - 32 **Dip F**, LoMenzo E, Sarotto L, Phillips E, Todeschini H, Nahmod M, Alle L, Schneider S, Kaja L, Boni L, Ferraina P, Carus T, Kokudo N, Ishizawa T, Walsh M, Simpfendorfer C, Mayank R, White K, Rosenthal RJ. Randomized Trial of Near-infrared Incisionless Fluorescent Cholangiography. *Ann Surg* 2019; **270**: 992-999 [PMID: [30614881](#) DOI: [10.1097/SLA.0000000000003178](#)]
 - 33 **Yoshiya S**, Minagawa R, Kamo K, Kasai M, Taketani K, Yukaya T, Kimura Y, Koga T, Kai M, Kajiyama K, Yoshizumi T. Usability of Intraoperative Fluorescence Imaging with Indocyanine Green During Laparoscopic Cholecystectomy After Percutaneous Transhepatic Gallbladder Drainage. *World J Surg* 2019; **43**: 127-133 [PMID: [30105635](#) DOI: [10.1007/s00268-018-4760-1](#)]
 - 34 **Kitamura H**, Tsuji T, Yamamoto D, Takahashi T, Kadota S, Kurokawa M, Bando H. Efficiency of fluorescent cholangiography during laparoscopic cholecystectomy for subvesical bile ducts: A case report. *Int J Surg Case Rep* 2019; **57**: 194-196 [PMID: [30981075](#) DOI: [10.1016/j.ijscr.2019.03.042](#)]
 - 35 **Iwasaki T**, Takeyama Y, Yoshida Y, Kawaguchi K, Matsumoto M, Murase T, Kamei K, Takebe A, Matsumoto I, Nakai T. Identification of aberrant subvesical bile duct by using intraoperative fluorescent cholangiography: A case report. *Int J Surg Case Rep* 2019; **61**: 115-118 [PMID: [31357101](#) DOI: [10.1016/j.ijscr.2019.07.013](#)]
 - 36 **Tsuruda Y**, Okumura H, Setoyama T, Hiwatashi K, Minami K, Ando K, Wada M, Maenohara S, Natsugoe S. Laparoscopic cholecystectomy with aberrant bile duct detected by intraoperative fluorescent cholangiography concomitant with angiography: A case report. *Int J Surg Case Rep* 2018; **51**: 14-16 [PMID: [30130667](#) DOI: [10.1016/j.ijscr.2018.08.009](#)]
 - 37 **Bozzay J**, Vicente D, Jessie EM, Rodriguez CJ. Identification of Abnormal Biliary Anatomy Utilizing Real-Time Near-Infrared Cholangiography: A Report of Two Cases. *Case Rep Gastrointest Med* 2017; **2017**: 8628206 [PMID: [28536662](#) DOI: [10.1155/2017/8628206](#)]
 - 38 **Asai Y**, Igami T, Ebata T, Yokoyama Y, Mizuno T, Yamaguchi J, Onoe S, Watanabe N, Nagino M. Application of fluorescent cholangiography during single-incision laparoscopic cholecystectomy in the cystohepatic duct without preoperative diagnosis. *ANZ J Surg* 2021; **91**: 470-472 [PMID: [32681758](#) DOI: [10.1111/ans.16162](#)]
 - 39 **Kim NS**, Jin HY, Kim EY, Hong TH. Cystic duct variation detected by near-infrared fluorescent cholangiography during laparoscopic cholecystectomy. *Ann Surg Treat Res* 2017; **92**: 47-50 [PMID: [28090506](#) DOI: [10.4174/astr.2017.92.1.47](#)]
 - 40 **Naganuma S**, Ishida H, Konno K, Hamashima Y, Hoshino T, Naganuma H, Komatsuda T, Ohyama Y, Yamada N, Ishida J, Masamune O. Sonographic findings of anomalous position of the gallbladder. *Abdom Imaging* 1998; **23**: 67-72 [PMID: [9437066](#) DOI: [10.1007/s002619900287](#)]
 - 41 **Nojiri M**, Igami T, Toyoda Y, Ebata T, Yokoyama Y, Sugawara G, Mizuno T, Yamaguchi J, Nagino M. Application of fluorescent cholangiography during single-incision laparoscopic cholecystectomy for cholecystitis with a right-sided round ligament: Preliminary experience. *J Minim Access Surg* 2018; **14**: 244-246 [PMID: [29226884](#) DOI: [10.4103/jmas.JMAS_159_17](#)]
 - 42 **Shanmugam V**, Beattie GC, Yule SR, Reid W, Loudon MA. Is magnetic resonance cholangiopancreatography the new gold standard in biliary imaging? *Br J Radiol* 2005; **78**: 888-893 [PMID: [16177010](#) DOI: [10.1259/bjr/51075444](#)]
 - 43 **Griffin N**, Charles-Edwards G, Grant LA. Magnetic resonance cholangiopancreatography: the ABC of MRCP. *Insights Imaging* 2012; **3**: 11-21 [PMID: [22695995](#) DOI: [10.1007/s13244-011-0129-9](#)]
 - 44 **Pesce A**, La Greca G, Esposto Ultimo L, Basile A, Puleo S, Palmucci S. Effectiveness of near-infrared fluorescent cholangiography in the identification of cystic duct-common hepatic duct anatomy in comparison to magnetic resonance cholangio-pancreatography: a preliminary study. *Surg Endosc* 2020; **34**: 2715-2721 [PMID: [31598878](#) DOI: [10.1007/s00464-019-07158-2](#)]

- 45 **Diana M**, Soler L, Agnus V, D'Urso A, Vix M, Dallemagne B, Faucher V, Roy C, Mutter D, Marescaux J, Pessaux P. Prospective Evaluation of Precision Multimodal Gallbladder Surgery Navigation: Virtual Reality, Near-infrared Fluorescence, and X-ray-based Intraoperative Cholangiography. *Ann Surg* 2017; **266**: 890-897 [PMID: [28742709](#) DOI: [10.1097/SLA.0000000000002400](#)]
- 46 **Hiwatashi K**, Okumura H, Setoyama T, Ando K, Ogura Y, Aridome K, Maenohara S, Natsugoe S. Evaluation of laparoscopic cholecystectomy using indocyanine green cholangiography including cholecystitis: A retrospective study. *Medicine (Baltimore)* 2018; **97**: e11654 [PMID: [30045318](#) DOI: [10.1097/MD.00000000000011654](#)]
- 47 **Pesce A**, Latteri S, Barchitta M, Portale TR, Di Stefano B, Agodi A, Russello D, Puleo S, La Greca G. Near-infrared fluorescent cholangiography - real-time visualization of the biliary tree during elective laparoscopic cholecystectomy. *HPB (Oxford)* 2018; **20**: 538-545 [PMID: [29292071](#) DOI: [10.1016/j.hpb.2017.11.013](#)]
- 48 **Pesce A**, Diana M. Critical View of Safety During Laparoscopic Cholecystectomy: From the Surgeon's Eye to Fluorescent Vision. *Surg Innov* 2018; **25**: 197-198 [PMID: [29557253](#) DOI: [10.1177/1553350618763200](#)]
- 49 **Dip FD**, Asbun D, Rosales-Velderrain A, Lo Menzo E, Simpfendorfer CH, Szomstein S, Rosenthal RJ. Cost analysis and effectiveness comparing the routine use of intraoperative fluorescent cholangiography with fluoroscopic cholangiogram in patients undergoing laparoscopic cholecystectomy. *Surg Endosc* 2014; **28**: 1838-1843 [PMID: [24414461](#) DOI: [10.1007/s00464-013-3394-5](#)]
- 50 **Lehrskov LL**, Westen M, Larsen SS, Jensen AB, Kristensen BB, Bisgaard T. Fluorescence or X-ray cholangiography in elective laparoscopic cholecystectomy: a randomized clinical trial. *Br J Surg* 2020; **107**: 655-661 [PMID: [32057103](#) DOI: [10.1002/bjs.11510](#)]
- 51 **Lim SH**, Tan HTA, Shelat VG. Comparison of indocyanine green dye fluorescent cholangiography with intra-operative cholangiography in laparoscopic cholecystectomy: a meta-analysis. *Surg Endosc* 2021; **35**: 1511-1520 [PMID: [33398590](#) DOI: [10.1007/s00464-020-08164-5](#)]
- 52 **Dip F**, Roy M, Lo Menzo E, Simpfendorfer C, Szomstein S, Rosenthal RJ. Routine use of fluorescent incisionless cholangiography as a new imaging modality during laparoscopic cholecystectomy. *Surg Endosc* 2015; **29**: 1621-1626 [PMID: [25277476](#) DOI: [10.1007/s00464-014-3853-7](#)]
- 53 **Quaresima S**, Balla A, Palmieri L, Seitaj A, Fingerhut A, Ursi P, Paganini AM. Routine near infra-red indocyanine green fluorescent cholangiography vs intraoperative cholangiography during laparoscopic cholecystectomy: a case-matched comparison. *Surg Endosc* 2020; **34**: 1959-1967 [PMID: [31309307](#) DOI: [10.1007/s00464-019-06970-0](#)]
- 54 **Osayi SN**, Wendling MR, Drosdeck JM, Chaudhry UI, Perry KA, Noria SF, Mikami DJ, Needleman BJ, Muscarella P 2nd, Abdel-Rasoul M, Renton DB, Melvin WS, Hazey JW, Narula VK. Near-infrared fluorescent cholangiography facilitates identification of biliary anatomy during laparoscopic cholecystectomy. *Surg Endosc* 2015; **29**: 368-375 [PMID: [24986018](#) DOI: [10.1007/s00464-014-3677-5](#)]
- 55 **Buchs NC**, Pugin F, Azagury DE, Jung M, Volonte F, Hagen ME, Morel P. Real-time near-infrared fluorescent cholangiography could shorten operative time during robotic single-site cholecystectomy. *Surg Endosc* 2013; **27**: 3897-3901 [PMID: [23670747](#) DOI: [10.1007/s00464-013-3005-5](#)]
- 56 **Aoki T**, Murakami M, Yasuda D, Shimizu Y, Kusano T, Matsuda K, Niiya T, Kato H, Murai N, Otsuka K, Kusano M, Kato T. Intraoperative fluorescent imaging using indocyanine green for liver mapping and cholangiography. *J Hepatobiliary Pancreat Sci* 2010; **17**: 590-594 [PMID: [19844652](#) DOI: [10.1007/s00534-009-0197-0](#)]
- 57 **Vlek SL**, van Dam DA, Rubinstein SM, de Lange-de Klerk ESM, Schoonmade LJ, Tuynman JB, Meijerink WJHJ, Ankersmit M. Biliary tract visualization using near-infrared imaging with indocyanine green during laparoscopic cholecystectomy: results of a systematic review. *Surg Endosc* 2017; **31**: 2731-2742 [PMID: [27844236](#) DOI: [10.1007/s00464-016-5318-7](#)]
- 58 **Dip F**, Nguyen D, Montorfano L, Szretter Noste ME, Lo Menzo E, Simpfendorfer C, Szomstein S, Rosenthal R. Accuracy of Near Infrared-Guided Surgery in Morbidly Obese Subjects Undergoing Laparoscopic Cholecystectomy. *Obes Surg* 2016; **26**: 525-530 [PMID: [26224370](#) DOI: [10.1007/s11695-015-1781-9](#)]
- 59 **Pax V**, Schneider-Koriath S, Scholz M, Wiefner R, Ludwig K. [Fluorescence Cholangiography in Comparison to Radiographic Cholangiography During Laparoscopic Cholecystectomy]. *Zentralbl Chir* 2018; **143**: 35-41 [PMID: [29166696](#) DOI: [10.1055/s-0043-117495](#)]
- 60 **Koong JK**, Ng GH, Ramayah K, Koh PS, Yoong BK. Early identification of the critical view of safety in laparoscopic cholecystectomy using indocyanine green fluorescence cholangiography: A randomised controlled study. *Asian J Surg* 2021; **44**: 537-543 [PMID: [33223453](#) DOI: [10.1016/j.asjsur.2020.11.002](#)]
- 61 **van den Bos J**, Schols RM, Luyer MD, van Dam RM, Vahrmeijer AL, Meijerink WJ, Gobardhan PD, van Dam GM, Bouvy ND, Stassen LP. Near-infrared fluorescence cholangiography assisted laparoscopic cholecystectomy vs conventional laparoscopic cholecystectomy (FALCON trial): study protocol for a multicentre randomised controlled trial. *BMJ Open* 2016; **6**: e011668 [PMID: [27566635](#) DOI: [10.1136/bmjopen-2016-011668](#)]
- 62 **Roy M**, Dip F, Nguyen D, Simpfendorfer CH, Menzo EL, Szomstein S, Rosenthal RJ. Fluorescent incisionless cholangiography as a teaching tool for identification of Calot's triangle. *Surg Endosc* 2017; **31**: 2483-2490 [PMID: [27778170](#) DOI: [10.1007/s00464-016-5250-x](#)]

- 63 **Rungsakulkij N**, Thewmorakot S, Suragul W, Vassanasiri W, Tangtawee P, Muangkaew P, Mingphruehdi S, Aeesoa S. Fluorescence cholangiography enhances surgical residents' biliary delineation skill for laparoscopic cholecystectomies. *World J Gastrointest Surg* 2020; **12**: 93-103 [PMID: [32218892](#) DOI: [10.4240/wjgs.v12.i3.93](#)]
- 64 **van de Graaf FW**, Zaïmi I, Stassen LPS, Lange JF. Safe laparoscopic cholecystectomy: A systematic review of bile duct injury prevention. *Int J Surg* 2018; **60**: 164-172 [PMID: [30439536](#) DOI: [10.1016/j.ijsu.2018.11.006](#)]
- 65 **Labib PL**, Aroori S. Intraoperative ultrasound vs fluorescence and X-ray cholangiography for the identification of bile duct stones, biliary anatomy and bile duct injury during laparoscopic cholecystectomy: Time for a randomized controlled trial? *Br J Surg* 2020; **107**: e563 [PMID: [32841376](#) DOI: [10.1002/bjs.11862](#)]
- 66 **Dili A**, Bertrand C. Laparoscopic ultrasonography as an alternative to intraoperative cholangiography during laparoscopic cholecystectomy. *World J Gastroenterol* 2017; **23**: 5438-5450 [PMID: [28839445](#) DOI: [10.3748/wjg.v23.i29.5438](#)]
- 67 **Machi J**, Johnson JO, Deziel DJ, Soper NJ, Berber E, Siperstein A, Hata M, Patel A, Singh K, Arregui ME. The routine use of laparoscopic ultrasound decreases bile duct injury: a multicenter study. *Surg Endosc* 2009; **23**: 384-388 [PMID: [18528611](#) DOI: [10.1007/s00464-008-9985-x](#)]
- 68 **Spinoglio G**, Lenti LM, Maglione V, Lucido FS, Priora F, Bianchi PP, Grosso F, Quarati R. Single-site robotic cholecystectomy (SSRC) versus single-incision laparoscopic cholecystectomy (SILC): comparison of learning curves. First European experience. *Surg Endosc* 2012; **26**: 1648-1655 [PMID: [22179472](#) DOI: [10.1007/s00464-011-2087-1](#)]
- 69 **Buchs NC**, Hagen ME, Pugin F, Volonte F, Bucher P, Schiffer E, Morel P. Intra-operative fluorescent cholangiography using indocyanin green during robotic single site cholecystectomy. *Int J Med Robot* 2012; **8**: 436-440 [PMID: [22648637](#) DOI: [10.1002/ics.1437](#)]
- 70 **Spinoglio G**, Priora F, Bianchi PP, Lucido FS, Licciardello A, Maglione V, Grosso F, Quarati R, Ravazzoni F, Lenti LM. Real-time near-infrared (NIR) fluorescent cholangiography in single-site robotic cholecystectomy (SSRC): a single-institutional prospective study. *Surg Endosc* 2013; **27**: 2156-2162 [PMID: [23271272](#) DOI: [10.1007/s00464-012-2733-2](#)]
- 71 **Maker AV**, Kunda N. A Technique to Define Extrahepatic Biliary Anatomy Using Robotic Near-Infrared Fluorescent Cholangiography. *J Gastrointest Surg* 2017; **21**: 1961-1962 [PMID: [28585107](#) DOI: [10.1007/s11605-017-3455-5](#)]
- 72 **Sharma S**, Huang R, Hui S, Smith MC, Chung PJ, Schwartzman A, Sugiyama G. The utilization of fluorescent cholangiography during robotic cholecystectomy at an inner-city academic medical center. *J Robot Surg* 2018; **12**: 481-485 [PMID: [29181777](#) DOI: [10.1007/s11701-017-0769-y](#)]
- 73 **Gangemi A**, Danilkowicz R, Elli FE, Bianco F, Masrur M, Giulianotti PC. Could ICG-aided robotic cholecystectomy reduce the rate of open conversion reported with laparoscopic approach? *J Robot Surg* 2017; **11**: 77-82 [PMID: [27435700](#) DOI: [10.1007/s11701-016-0624-6](#)]
- 74 **Dip F**, Sarotto L, Roy M, Lee A, LoMenzo E, Walsh M, Carus T, Schneider S, Boni L, Ishizawa T, Kokudo N, White K, Rosenthal RJ. Incisionless fluorescent cholangiography (IFC): a pilot survey of surgeons on procedural familiarity, practices, and perceptions. *Surg Endosc* 2020; **34**: 675-685 [PMID: [31062156](#) DOI: [10.1007/s00464-019-06814-x](#)]
- 75 **Brunt LM**, Deziel DJ, Telem DA, Strasberg SM, Aggarwal R, Asbun H, Bonjer J, McDonald M, Alseidi A, Ujiki M, Riall TS, Hammill C, Moulton CA, Pucher PH, Parks RW, Ansari MT, Connor S, Dirks RC, Anderson B, Altieri MS, Tsamalaidze L, Stefanidis D; and the Prevention of Bile Duct Injury Consensus Work Group. Safe Cholecystectomy Multi-society Practice Guideline and State of the Art Consensus Conference on Prevention of Bile Duct Injury During Cholecystectomy. *Ann Surg* 2020; **272**: 3-23 [PMID: [32404658](#) DOI: [10.1097/SLA.0000000000003791](#)]
- 76 **Dip F**, Boni L, Bouvet M, Carus T, Diana M, Falco J, Gurtner GC, Ishizawa T, Kokudo N, Lo Menzo E, Low PS, Masia J, Muehrcke D, Papay FA, Pulitano C, Schneider-Koraith S, Sherwinter D, Spinoglio G, Stassen L, Urano Y, Vahrmeijer A, Vibert E, Warram J, Wexner SD, White K, Rosenthal RJ. Consensus Conference Statement on the General Use of Near-Infrared Fluorescence Imaging and Indocyanine Green Guided Surgery: Results of a Modified Delphi Study. *Ann Surg* 2020 [PMID: [33214476](#) DOI: [10.1097/SLA.0000000000004412](#)]
- 77 **Benya R**, Quintana J, Brundage B. Adverse reactions to indocyanine green: a case report and a review of the literature. *Cathet Cardiovasc Diagn* 1989; **17**: 231-233 [PMID: [2670244](#) DOI: [10.1002/ccd.1810170410](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

